There are 2789 resources available
589P - Dynamics of peripheral blood immune profiling associated with tumour progression in metastatic castration resistant prostate cancer (mCRPC)
Presenter: Enrique Perez Navarro
Session: ePoster Display
575TiP - Cabozantinib plus atezolizumab in advanced and progressive neoplasms of the endocrine system: A multicohort phase II trial (CABATEN trial / GETNE-T1914)
Presenter: Enrique Grande
Session: ePoster Display
581P - Patient (pt) reported pain in men with metastatic castration-resistant prostate cancer (mCRPC) receiving talazoparib (TALA): TALAPRO-1
Presenter: Fred Saad
Session: ePoster Display
582P - Health-related quality of life (HRQoL) at final analysis of the GALAHAD study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and DNA repair defects (DRD)
Presenter: Matthew Smith
Session: ePoster Display
475P - A phase Ib study of NUC-3373, a targeted inhibitor of thymidylate synthase, in combination with standard therapies in patients with advanced colorectal cancer (NuTide:302)
Presenter: Jordan Berlin
Session: ePoster Display
476P - Open-label phase I/II study evaluating the tolerability and antitumor activity of selinexor (SEL) and pembrolizumab (pembro) in colorectal cancer (CRC)
Presenter: Talia Shentzer Kutiel
Session: ePoster Display
477P - Utilisation and predictors of genomic testing prior to first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC)
Presenter: Heinz Josef Lenz
Session: ePoster Display
478P - TA-ness classification discriminates RAS wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts) who may benefit from antiEGFR treatment
Presenter: Cristina Santos
Session: ePoster Display